Presence of adequate intravitreal concentrations of daptomycin after systemic intravenous administration in a patient with endogenous endophthalmitis

Pharmacotherapy

Volumn 30, Issue 12, 2010, Pages 1247-1251

  Sheridan, Kathleen R ^a   Potoski, Brian A ^a,b   Shields, Ryan K ^a   Nau, Gerard J ^a,c  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Daptomycin; Endophthalmitis; Infectious diseases; Methicillin resistant Staphylococcus aureus; MRSA; Ophthalmology

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; DAPTOMYCIN; VANCOMYCIN;

ADULT; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; BACTERIUM ISOLATE; CASE REPORT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; ENDOPHTHALMITIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PERICARDIAL EFFUSION; PERICARDITIS; VITREOUS BODY;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; ENDOPHTHALMITIS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN; VITREOUS BODY;

EID: 78650208527     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.12.1247     Document Type: Article

References (18)

1. Deramo VA, Lai JC, Winokur J, Luchs J, Udell IJ. Visual outcome and bacterial sensitivity after methicillin-resistant Staphylococcus aureus-associated acute endophthalmitis. Am J Ophthalmol 2008;145:413-7.
2. Ness T, Schneider C. Endogenous endophthalmitis caused by methicillin-resistant Staphylococcus aureus (MRSA). Retina 2009;29:831-4.
3. Ferencz JR, Assia EI, Diamantstein L, Rubinstein E. Vancomycin concentration in the vitreous after intravenous and intravitreal administration for postoperative endophthalmitis. Arch Ophthal 1999;117:1023-7.
4. Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 2003;52:405-11.
5. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003;41:5113-20.
6. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin- susceptible clones of Staphylococcus aureus. J Clin Microbiol 2000;38:1008-15.
7. Zhang K, McClure JA, Elsayed S, Louie T, Conly JM. Novel multiplex PCR assay for simultaneous identification of community-associated methicillin-resistant Staphylococcus aureus strains USA300 and USA400 and detection of mecA and Panton-Valentine leukocidin genes, with discrimination of Staphylococcus aureus from coagulase-negative staphylococci. J Clin Microbiol 2008;46:1118-22.
8. Goering RV. Pulsed-field gel electrophoresis. In: Persing DH, Tenover FC, Versalovic J, et al, eds. Molecular microbiology: diagnostic principles and practice. Washington, DC: American Society for Microbiology Press, 2004:185-96.
9. Meredith TA, Aguilar HE, Shaarawy A, Kincaid M, Dick J, Niesman MR. Vancomycin levels in the vitreous cavity after intravenous administration. Am J Ophthalmol 1995;119:774-8.
10. Cubist Pharmaceuticals. Cubicin (daptomycin) package insert. Lexington, MA; August 2010.
11. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high dose (> or = 8mg/kg) daptomycin therapy. Ann Pharmacother 2009;43:1211-19.
12. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003;47:1598-603.
13. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98.
14. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-6. (Pubitemid 351521995)
15. Rutar T, Chambers HF, Crawford JB. Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant Staphylococcus aureus. Ophthalmology 2006;113:1455-62. (Pubitemid 44108175)
16. Fiscella RG, Lai WW, Buerk B, et al. Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration. Ophthalmology 2004;111:1191-5.
17. Rybak MJ, Capelletty DM, Moldovan T, et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 1998;42:721-4.
18. Andes D, van Ogrrop ML, Peng J, Craig WA. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002;46:3484-9.